Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis

Alexandra Snyder1,2, Tavi Nathanson3, Samuel A. Funt1,2, Arun Ahuja3, Jacqueline Buros Novik3, Matthew D. Hellmann1,2, Eliza Chang3, Bulent Arman Aksoy3, Hikmat Al-Ahmadie4, Erik Yusko5, Marissa Vignali5, Sharon Benzeno5, Mariel Boyd1, Meredith Moran1, Gopa Iyer1,2, Harlan S. Robins5,6, Elaine R. Mardis7, Taha Merghoub1, Jeff Hammerbacher3, Jonathan E. Rosenberg1, Dean F. Bajorin1,2 1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America, 2Department of Medicine, Weill Cornell Medical College, New York, New York, United States of America, 3Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America, 4Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America, 5Adaptive Biotechnologies, Seattle, Washington, United States of America, 6Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America, 7Department of Pediatrics, Institute for Genomic Medicine, The Research Institute at Nationwide Children’s Hospital, The Ohio State University College of Medicine, Columbus, Ohio, United States of America